The announcement of a 40% workforce reduction due to a delay in the CORAL Phase 2b study and the subsequent lack of expected external funding has negatively impacted investor sentiment towards Gritstone Bio Inc. This is a significant operational change that directly affects the company's financial stability and operational efficiency in the short term. However, the company's commitment to its core programs and upcoming milestones, such as the GRANITE study, may provide some reassurance to investors about its long-term prospects.